Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/01.NPR.0000798256.17155.86 | DOI Listing |
JAMA Dermatol
January 2025
Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland.
Dermatol Ther (Heidelb)
January 2025
1st Department of Dermatology and Venereology, Medical School of Athens, Andreas Sygros Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Introduction: Results from randomized controlled trials of upadacitinib, a Janus kinase (JAK) inhibitor, have led to its approval for the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged ≥ 12 years. The aim of this study was to report the effectiveness and safety of upadacitinib in real-world settings over a period of 96 weeks.
Methods: This retrospective study included all patients treated with upadacitinib at our centre between April 2022 and September 2024.
Arch Dermatol Res
January 2025
Department of Ultrasound, Affiliated Hospital of Nantong University, Nantong, 226001, China.
Arch Dermatol Res
January 2025
The Dermatology Department of the Central Military Hospital of the Ministy of Defense, Baku, Azerbaijan.
The use of antidepressant medications in the treatment of lichen simplex chronicus (LSC) also known as neurodermatitis, is not well-documented in the literature. The primary aim of our study is to evaluate the impact of duloxetine 30 mg on the quality of life in patients with LSC, focusing on both pruritus and psychopathological aspects. The secondary aim is to investigate the relationship between LSC and anxiety and depression.
View Article and Find Full Text PDFArch Dermatol Res
January 2025
Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!